| Dr Katarzyna M Lechliter, MD | |
|
2001 Medical Parkway, Acute Care Pavilion, Annapolis, MD 21401-3280 | |
| (443) 481-1000 | |
| (443) 481-1687 |
| Full Name | Dr Katarzyna M Lechliter |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 19 Years |
| Location | 2001 Medical Parkway, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487988440 | NPI | - | NPPES |
| V8260026 | Other | CAREFIRST | |
| 607156012 | Other | DEPT OF LABOR | |
| 418651600 | Medicaid | MD | |
| 95624103 | Other | CAREFIRST |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | D69449 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anne Arundel Medical Center | Annapolis, MD | Hospital |
| Medstar Good Samaritan Hospital | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Luminis Health Medical Group, Llc | 2860447315 | 431 |
News Archive
Adults with diabetes and multi-vessel coronary heart disease who underwent cardiac bypass surgery had better overall heart-related outcomes than those who underwent an artery-opening procedure to improve blood flow to the heart muscle, according to the results from an international study. The research was supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied. However, the potential therapeutic role of PPAR-γ agonists has been questioned, based on contradictory results. Studies using animal models of colon cancer found that PPAR-γ agonists increased the development of colon tumors.
Roche NimbleGen, announced today a company-wide initiative to implement Good Manufacturing Processes (GMP) for its suite of DNA microarrays. The implementation of GMP will cover the full scope of processes from development through manufacturing and will include all locations. The company plans on achieving GMP compliance followed by subsequent submission for clearance or approval of select array products to the US Food and Drug Administration.
NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has completed a $33 million Series A financing led by Third Rock Ventures and Prospect Venture Partners. The company also announced the establishment of its corporate headquarters in Cambridge, Mass. where Charles Carignan, M.D., serves as president and chief executive officer.
› Verified 9 days ago
| Entity Name | Luminis Health Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073580205 PECOS PAC ID: 2860447315 Enrollment ID: O20050317000146 |
News Archive
Adults with diabetes and multi-vessel coronary heart disease who underwent cardiac bypass surgery had better overall heart-related outcomes than those who underwent an artery-opening procedure to improve blood flow to the heart muscle, according to the results from an international study. The research was supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied. However, the potential therapeutic role of PPAR-γ agonists has been questioned, based on contradictory results. Studies using animal models of colon cancer found that PPAR-γ agonists increased the development of colon tumors.
Roche NimbleGen, announced today a company-wide initiative to implement Good Manufacturing Processes (GMP) for its suite of DNA microarrays. The implementation of GMP will cover the full scope of processes from development through manufacturing and will include all locations. The company plans on achieving GMP compliance followed by subsequent submission for clearance or approval of select array products to the US Food and Drug Administration.
NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has completed a $33 million Series A financing led by Third Rock Ventures and Prospect Venture Partners. The company also announced the establishment of its corporate headquarters in Cambridge, Mass. where Charles Carignan, M.D., serves as president and chief executive officer.
› Verified 9 days ago
| Entity Name | Hospitalist Medicine Physicians Of Maryland Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992945471 PECOS PAC ID: 8729138003 Enrollment ID: O20120223000194 |
News Archive
Adults with diabetes and multi-vessel coronary heart disease who underwent cardiac bypass surgery had better overall heart-related outcomes than those who underwent an artery-opening procedure to improve blood flow to the heart muscle, according to the results from an international study. The research was supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied. However, the potential therapeutic role of PPAR-γ agonists has been questioned, based on contradictory results. Studies using animal models of colon cancer found that PPAR-γ agonists increased the development of colon tumors.
Roche NimbleGen, announced today a company-wide initiative to implement Good Manufacturing Processes (GMP) for its suite of DNA microarrays. The implementation of GMP will cover the full scope of processes from development through manufacturing and will include all locations. The company plans on achieving GMP compliance followed by subsequent submission for clearance or approval of select array products to the US Food and Drug Administration.
NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has completed a $33 million Series A financing led by Third Rock Ventures and Prospect Venture Partners. The company also announced the establishment of its corporate headquarters in Cambridge, Mass. where Charles Carignan, M.D., serves as president and chief executive officer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Katarzyna M Lechliter, MD Po Box 12622, Belfast, ME 04915-4017 Ph: (443) 481-6566 | Dr Katarzyna M Lechliter, MD 2001 Medical Parkway, Acute Care Pavilion, Annapolis, MD 21401-3280 Ph: (443) 481-1000 |
News Archive
Adults with diabetes and multi-vessel coronary heart disease who underwent cardiac bypass surgery had better overall heart-related outcomes than those who underwent an artery-opening procedure to improve blood flow to the heart muscle, according to the results from an international study. The research was supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied. However, the potential therapeutic role of PPAR-γ agonists has been questioned, based on contradictory results. Studies using animal models of colon cancer found that PPAR-γ agonists increased the development of colon tumors.
Roche NimbleGen, announced today a company-wide initiative to implement Good Manufacturing Processes (GMP) for its suite of DNA microarrays. The implementation of GMP will cover the full scope of processes from development through manufacturing and will include all locations. The company plans on achieving GMP compliance followed by subsequent submission for clearance or approval of select array products to the US Food and Drug Administration.
NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has completed a $33 million Series A financing led by Third Rock Ventures and Prospect Venture Partners. The company also announced the establishment of its corporate headquarters in Cambridge, Mass. where Charles Carignan, M.D., serves as president and chief executive officer.
› Verified 9 days ago
Gashaw Adugna Dadi, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 240-495-4189 | |
Dr. Eugene Thomas Manion, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 900 Bestgate Road, Suite 303, Annapolis, MD 21401 Phone: 410-224-8220 Fax: 410-841-2482 | |
Dr. Lisa A Dimarzio, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2003 Medical Parkway, Suite 100, Annapolis, MD 21401 Phone: 410-573-1110 Fax: 410-266-0714 | |
Dr. Richard A Bernstein, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 133 Defense Hwy, Suite 109, Annapolis, MD 21401 Phone: 401-224-5558 Fax: 410-224-7321 | |
Dr. Jonathan A Altschuler, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Ste 500, Annapolis, MD 21401 Phone: 410-573-6480 Fax: 410-573-9413 | |
Dr. Ira M Weinstein, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Medical Pkwy, Suite 607, Annapolis, MD 21401 Phone: 410-266-1644 Fax: 410-266-1642 | |
Dr. James M Blake, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 820 Bestgate Road, Suite 2a, Annapolis, MD 21401 Phone: 410-224-2116 Fax: 410-224-2118 |